Key result
Chemotherapy induces potentially permanent or reversible cardiac dysfunction in ~10% of patients.
Why the study?
Cancer therapy-related cardiac dysfunction occurs in approximately 10% of chemotherapy patients, making risk assessment, recognition, and prevention crucial.
This review highlights the importance of risk assessment, recognition, and prevention of cancer therapy-related cardiac dysfunction, which affects approximately 10% of patients.
Warrants cardiac monitoring during chemotherapy; leaves open optimal prevention and risk-stratification strategies.
Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It can be classified as direct (dose-dependent vs dose-independent) or indirect, either case being potentially permanent or reversible. Risk assessment, recognition, and prevention of CTRCD are crucial.
No takes yet. Share an insight, caveat, or question.
Perez et al. (2019) studied this question. Chemotherapy induces cancer therapy-related cardiac dysfunction in approximately 10% of patients, manifesting as potentially permanent or reversible direct or indirect effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: